Axsome Therapeutics Impresses with Strong Growth in Antidepressant Auvelity
Reading Time: 1 minute
Business Driver : The US biopharmaceutical company Axsome Therapeutics (AXSM) specializes in drugs for the treatment of central nervous system (CNS) disorders. One of the main growth drivers is the FDA-approved antidepressant Auvelity (AXS-05), while it also has another medication, Sunosi (Solriamfetol), for the treatment of adults suffering from excessive daytime sleepiness (EDS). With a promising pipeline of more than 5 additional candidates in advanced clinical trials, Axsome Therapeutics presents good growth opportunities in the medium term....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
